Celltrion Q2 net profit surges sixfold driven by biosimilar demand

Celltrion reported a nearly sixfold increase in Q2 net profit, attributed to robust sales of its biosimilar product portfolio. The performance reflects sustained market penetration in the global biopharmaceutical sector, though specific regional growth drivers remain unquantified in the initial report.